Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer (Q33348261)

26 July 2017

title

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer (English)

1 reference

26 July 2017

1 reference

1 reference

8

Hisashi Noguchi

1 reference

26 July 2017

Takashi Hirose

1

1 reference

26 July 2017

Naoya Horichi

2

1 reference

26 July 2017

Tohru Ohmori

3

1 reference

26 July 2017

Keiichi Ogura

4

1 reference

26 July 2017

Takamichi Hosaka

5

1 reference

26 July 2017

Kohichi Ando

6

1 reference

26 July 2017

Hiroo Ishida

7

1 reference

26 July 2017

Mitsuru Adachi

9

1 reference

26 July 2017

publication date

1 June 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

40

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

333-338

1 reference

Management of small-cell cancer of the lung

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Second-line chemotherapy and its evaluation in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)50075-8

7 January 2021

10.1016/S0169-5002(03)00075-8

Identifiers

DOI

1 reference

26 July 2017

1 reference